AVANIR to Present at the Lazard Healthcare Conference
ALISO VIEJO, Calif., November 11, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18th at 3:15 p.m. Eastern time (12:15 p.m. Pacific time) at the St. Regis in New York. The Lazard Healthcare Conference provides the opportunity for participating companies to present to top institutional investors and industry experts.
A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the Lazard Healthcare Conference will be available on the Company's website for 30 days.
AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.
To be included on AVANIR's e-mail alert list, click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0.
AVANIR Investor Contacts
Nov 11, 2009